Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mivacurium chloride--a comparative profile

C Diffenbach1, W Buzello, H Mellinghoff

  • 1Klinik für Anästhesiologie, Universität zu Köln, Cologne, Germany.

Acta Anaesthesiologica Scandinavica. Supplementum
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Possible underestimation of histamine releasing potency of cisatracurium?

European journal of anaesthesiology·2005
Same author

Anaphylactoid reactions after cisatracurium administration in six patients.

Anesthesia and analgesia·2001
Same author

Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients.

British journal of anaesthesia·1999
Same author

Mivacurium for muscle relaxation in a child with Duchenne's muscular dystrophy.

Anesthesia and analgesia·1999
Same author

Pseudocholinesterase-activity reduction during cardiopulmonary bypass: the role of dilutional processes and pharmacological agents.

General pharmacology·1999
Same author

Lactated Ringer's solution versus hydroxyethyl starch for volume replacement in autologous blood donors with cardiovascular disease: a controlled, randomized trial.

Vox sanguinis·1998
Same journal

Abstracts from the Scandinavian Society of Anaesthesiologists, 30th Congress, 10-13 June 2009, Odense, Denmark.

Acta anaesthesiologica Scandinavica. Supplementum·2009
Same journal

Abstracts from the 29th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, 5-8 September 2007, Goteborg, Sweden.

Acta anaesthesiologica Scandinavica. Supplementum·2007
Same journal

Abstracts from the 28th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Reykjavik, Iceland.

Acta anaesthesiologica Scandinavica. Supplementum·2005
Same journal

Abstracts from the 27th Congress of The Scandinavian Society of Anaesthesiology and Intensive Care Medicine. August 16-20, 2003, Helsinki, Finland.

Acta anaesthesiologica Scandinavica. Supplementum·2003
Same journal

Abstracts from the 26th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. June 13-17, 2001. Tromso, Norway.

Acta anaesthesiologica Scandinavica. Supplementum·2001
Same journal

The Scandinavian Society of Anaesthesiologists 25th Congress. Aarhus, Denmark, June 9-11, 1999. Abstracts.

Acta anaesthesiologica Scandinavica. Supplementum·1999
See all related articles

Mivacurium, a benzylisoquinoline muscle relaxant, offers rapid onset and short duration due to plasma cholinesterase breakdown. It provides flexible muscle paralysis control, potentially replacing suxamethonium in elective procedures.

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • Mivacurium is a novel, short-acting, nondepolarizing neuromuscular blocking agent.
  • It belongs to the benzylisoquinoline class of muscle relaxants.

Purpose of the Study:

  • To evaluate the pharmacodynamic profile of mivacurium.
  • To compare its potency and duration of action with vecuronium and atracurium.
  • To assess its suitability for tracheal intubation and prolonged surgical procedures.

Main Methods:

  • Determined the dose-response relationship, establishing the ED95 (dose for 95% twitch inhibition).
  • Assessed onset time for tracheal intubation and recovery profiles (DUR25%, recovery index) after bolus injection and continuous infusion.
  • Compared mivacurium's effects with those of vecuronium, atracurium, and suxamethonium.

Related Experiment Videos

Main Results:

  • Mivacurium ED95 is 60-80 µg/kg, showing it is less potent than vecuronium but more potent than atracurium.
  • Tracheal intubation is achievable within 2.5 minutes with 2-3 x ED95.
  • Recovery from neuromuscular blockade (DUR25%) is faster than with equipotent doses of atracurium or vecuronium, but longer than suxamethonium.
  • Continuous infusion allows for flexible control of muscle paralysis with a favorable 6-minute recovery index.

Conclusions:

  • Mivacurium offers a desirable pharmacokinetic profile, bridging the gap between short-acting suxamethonium and intermediate-acting agents.
  • Its rapid metabolism by plasma cholinesterase ensures a predictable and manageable duration of action.
  • Mivacurium presents a viable alternative to suxamethonium for elective surgeries requiring neuromuscular blockade.